Unicycive Therapeutics (UNCY) Competitors $4.29 +0.09 (+2.14%) Closing price 04:00 PM EasternExtended Trading$4.28 -0.01 (-0.35%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock UNCY vs. SGMT, SOPH, AARD, FENC, TLSA, GALT, ALEC, TVRD, MNPR, and CRGXShould you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include Sagimet Biosciences (SGMT), SOPHiA GENETICS (SOPH), Aardvark Therapeutics (AARD), Adherex Technologies (FENC), Tiziana Life Sciences (TLSA), Galectin Therapeutics (GALT), Alector (ALEC), Tvardi Therapeutics (TVRD), Monopar Therapeutics (MNPR), and CARGO Therapeutics (CRGX). These companies are all part of the "pharmaceutical products" industry. Unicycive Therapeutics vs. Its Competitors Sagimet Biosciences SOPHiA GENETICS Aardvark Therapeutics Adherex Technologies Tiziana Life Sciences Galectin Therapeutics Alector Tvardi Therapeutics Monopar Therapeutics CARGO Therapeutics Sagimet Biosciences (NASDAQ:SGMT) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends. Is SGMT or UNCY more profitable? Sagimet Biosciences' return on equity of -39.88% beat Unicycive Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sagimet BiosciencesN/A -39.88% -38.40% Unicycive Therapeutics N/A -243.13%-119.46% Do analysts prefer SGMT or UNCY? Sagimet Biosciences currently has a consensus price target of $25.67, suggesting a potential upside of 262.52%. Unicycive Therapeutics has a consensus price target of $60.00, suggesting a potential upside of 1,301.87%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Sagimet Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sagimet Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has stronger earnings and valuation, SGMT or UNCY? Unicycive Therapeutics has lower revenue, but higher earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSagimet Biosciences$2M115.12-$45.57M-$1.83-3.87Unicycive Therapeutics$680K111.15-$36.73M-$4.12-1.04 Do insiders & institutionals hold more shares of SGMT or UNCY? 87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 14.7% of Sagimet Biosciences shares are held by company insiders. Comparatively, 10.7% of Unicycive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, SGMT or UNCY? Sagimet Biosciences has a beta of 3.37, suggesting that its stock price is 237% more volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Does the media favor SGMT or UNCY? In the previous week, Unicycive Therapeutics had 18 more articles in the media than Sagimet Biosciences. MarketBeat recorded 20 mentions for Unicycive Therapeutics and 2 mentions for Sagimet Biosciences. Unicycive Therapeutics' average media sentiment score of 0.26 beat Sagimet Biosciences' score of 0.26 indicating that Unicycive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Unicycive Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummarySagimet Biosciences beats Unicycive Therapeutics on 9 of the 16 factors compared between the two stocks. Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UNCY vs. The Competition Export to ExcelMetricUnicycive TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$75.59M$2.78B$5.76B$9.72BDividend YieldN/A1.67%4.40%4.10%P/E Ratio-1.0422.2230.1925.84Price / Sales111.15748.28473.64122.75Price / CashN/A26.0925.7828.79Price / Book5.945.529.425.99Net Income-$36.73M$31.83M$3.27B$265.29M7 Day Performance4.90%1.08%2.05%2.53%1 Month Performance-12.11%0.83%3.58%0.93%1 Year Performance13.23%6.98%30.09%18.70% Unicycive Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UNCYUnicycive Therapeutics2.5798 of 5 stars$4.29+2.1%$60.00+1,298.6%+11.1%$75.76M$680K-1.049Analyst DowngradeSGMTSagimet Biosciences2.8131 of 5 stars$7.55-1.6%$25.67+240.0%+141.8%$235.28M$2M-4.138SOPHSOPHiA GENETICS2.9261 of 5 stars$3.49+0.6%$8.00+129.2%-3.5%$234.50M$65.17M-7.93520Positive NewsAARDAardvark TherapeuticsN/A$10.44-3.2%$32.80+214.2%N/A$233.89MN/A0.0018FENCAdherex Technologies1.9304 of 5 stars$8.20-1.9%$13.33+62.6%+51.9%$232.52M$47.54M-19.5210News CoverageAnalyst RevisionTLSATiziana Life Sciences0.5423 of 5 stars$1.89-4.1%N/A+68.9%$230.19MN/A0.008GALTGalectin Therapeutics2.3789 of 5 stars$3.90+9.2%$6.00+53.8%+77.5%$228.70MN/A-6.099ALECAlector3.8626 of 5 stars$2.13-5.3%$4.17+95.6%-52.5%$227.73M$100.56M-1.84270TVRDTvardi TherapeuticsN/A$24.74+3.1%$64.25+159.7%N/A$224.66M$7.14M0.0080News CoverageMNPRMonopar Therapeutics2.7243 of 5 stars$34.26-4.1%$60.00+75.1%+1,147.5%$220.33MN/A-10.2910CRGXCARGO Therapeutics2.165 of 5 stars$4.47-1.5%$15.40+244.5%N/A$219.57MN/A-0.96116Analyst UpgradeHigh Trading Volume Related Companies and Tools Related Companies Sagimet Biosciences Alternatives SOPHiA GENETICS Alternatives Aardvark Therapeutics Alternatives Adherex Technologies Alternatives Tiziana Life Sciences Alternatives Galectin Therapeutics Alternatives Alector Alternatives Tvardi Therapeutics Alternatives Monopar Therapeutics Alternatives CARGO Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UNCY) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access